A four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and fluorouracil—together referred to as NALIRIFOX—has been approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of metastatic pancreatic adenocarcinoma. ...
Lung cancer was the most common primary indication (25 [24.0%]), and small molecules were the most common drug type (48 [46.2%]). Most submissions were for the advanced or metastatic setting (97 [93.3%]), with 37 (35.6%) for treatment in the first line (eTables 2 and 3 in the ...
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia Tan and colleagues conducted a single-cell multiomic analysis of T cell acute lymphoblastic leukemia and identified a treatment-resistant subpopulation of bone marrow progen...
the mechanisms of action for this remain unclear. In this Perspective, Letai and de The assess the existing mechanisms proposed for the success of chemotherapy, identify gaps in our understanding and suggest principles for improving the utility of conventional chemotherapy to enhance treatment efficacy...
Fayers P, Bottomley A; EORTC Quality of Life Group; Quality of Life Unit; European Organisation for Research and Treatment of Cancer. Quality of life research within the EORTC: the EORTC QLQ-C30. Eur J Cancer. 2002;38(suppl 4):S125-S133. doi:10.1016/S0959-8049(01)00448-...
In another study – only one group received Xeloda, while women in the other group were given placebo pills. The treatment was given in six or eight three-week “cycles,” with two weeks on the drug, one week off. Five years later, 89% of Xeloda patients were still alive, compared wit...
SCCA knew when patients checked in and when they left the patient bay, but they also wanted to dig deeper to understand how long patients wait before their drug is infused or how long they wait once infusion stops and they depart the clinic. The Clinical Analytics Team,...
Outcomes4Me currently supports breast cancer and lung cancer patients. *** Outcomes4Me Featured Tools & Resources • Personalized treatment path – get a snapshot of recommended treatment options, drug information, and procedure alternatives based on your medical records history. • Clinical trial...
Cost Estimates for New Drug Approval in the Pharmaceutical Industrya View LargeDownload Supplement. eTable 1. Description and Key Findings of the 82 Practice-Influential Phase 3 Cancer Treatment Clinical Trials at SWOG eTable 2. NCCN-Cited Phase 3 Trials Determined Not to Be Practice Influential ...
Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. F